Trial Search Results

The Safety and Tolerability of Pirfenidone for BOS After HCT

This is a phase 1, non-randomized, single-arm, open label, single center clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopoietic cell transplant.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Genentech, Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: Pirfenidone 267 MG [Esbriet]

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Age > 18 years at randomization

   2. Clinical symptoms (e.g., dyspnea or cough) consistent with BOS of ≥ 2 months duration

   3. Presence of cGVHD in an organ other than lung

   4. Subjects must have had recent pulmonary function test (PFTs) measured for at least 3
   months prior to study enrollment that show:

      1. A decrease in %FVC and/or %FEV1 ≥ 20% at Screening compared with pre-transplant
      baseline.

      2. Bronchodilator response on PFT testing that results in an FEV1 < 75%

   5. Diagnosis of BOS by one of the following criteria:

      1. Transbronchial or surgical lung biopsy demonstrating the obliterative
      bronchiolitis lesion

      2. Volumetric CT scan with lung density analysis with ≥ 28% air trapping (1).

      3. NIH-based PFT criteria for the diagnosis of BOS: FEV1/FVC <0.7 and FEV1 < 75%

      4. Evidence of clinical improvement after treatment for BOS has been initiated.

   6. No features supporting an alternative diagnosis by transbronchial biopsy,
   bronchoalveolar lavage (BAL), surgical lung biopsy, culture and non-culture based
   data, if performed

   7. Adequate organ and marrow function including: liver function as defined by a total
   bilirubin below the upper limit of normal (ULN), excluding patients with Gilbert's
   syndrome; AST/SGOT or ALT/SGPT < 3 x ULN; alkaline phosphatase < 2.5 x ULN; renal
   function as defined by a CrCl > 30 mL/min, calculated using the Cockcroft-Gault
   formula; cardiac electrophysiologic stability as defined by an electrocardiogram (ECG)
   with a QTc interval < 500 msec at Screening; and bone marrow function as defined by a
   white blood cell count > 3 K/µL, an absolute neutrophil count > 15 K/µL and a platelet
   count > 20 K/µL

   8. Life expectancy > 6 months

   9. Participants must be able to understand and sign a written informed consent form and
   understand the importance of adherence to study treatment and protocol. In addition,
   participants must demonstrate a willingness to follow all study requirements,
   including the concomitant medication restrictions, throughout the study

Exclusion Criteria:

   1. Any condition that, in the opinion of the investigator, might be significantly
   exacerbated by the known side effects associated with the administration of
   pirfenidone e.g., presence of active GVHD of the gastrointestinal tract as manifested
   by rising liver function tests (LFTs) prior to initiation of study treatment

   2. Uncontrolled infection

   3. Major surgery within the past 2 months

   4. The use of another investigational drug within the previous 30 days.

   5. Inability to attend scheduled clinic visits

   6. Inability to perform pulmonary function testing

   7. Significant clinical change in health in the past 30 days

   8. Body mass index (BMI) < 17.5

   9. Life expectancy < 6 months due to any condition other than BOS that, in the opinion of
   the investigator, is likely to result in the death of the patient.

10. History of unstable or deteriorating cardiac or pulmonary disease (other than BOS)
   within the previous 6 months, including but not limited to the following:

      1. Unstable angina pectoris or myocardial infarction

      2. Congestive heart failure requiring hospitalization

      3. Uncontrolled clinically significant arrhythmias

11. Pregnancy or lactation.

12. Family or personal history of long QT syndrome

13. Investigational therapy, defined as any drug that has not been approved for marketing
   for any indication in cGVHD will be restricted from the study

14. The following medications may significantly increase the level of Pirfenidone and
   should not be taken concurrently including: fluvoxamine, ciprofloxacin > 500mg twice
   daily, systemically administered aminolevulinic acid, vemurafenib and enoxacin. Any
   other strong inhibitors of P450 isoenzymes CYP1A2, CYP2C9, 2C19, 2D6, and 2E1 should
   be avoided. Participants that cannot take alternative medications to those listed
   above will be excluded from this study.

Laboratory Exclusions

   1. Any of the following LFT criteria above specified limits: total bilirubin above the
   upper limit of normal (ULN), excluding patients with Gilbert's syndrome; aspartate or
   alanine aminotransferase (AST/SGOT or ALT/SGPT) >3 × ULN; alkaline phosphatase >2.5 ×
   ULN

   2. Creatinine clearance (CrCl) <30 mL/min, calculated using the Cockcroft-Gault formula

   3. Electrocardiogram (ECG) with a QTc interval >500 msec at Screening

Medication Exclusions

1. Prior use of pirfenidone or known hypersensitivity to any of the components of study
treatment.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Joe L Hsu, MD, MPH
650-725-9536